한글목차

세계의 갑상선 질환의 진단 및 치료 시장 규모는 2024년 155억 달러, 2025년 163억 달러에서 2030년에는 210억 달러에 달할 것으로 예측되며, 2025년부터 2030년까지의 예측 기간 동안 CAGR 5.2%로 성장할 전망입니다.

북미 시장은 2024년의 66억 달러, 2025년 69억 달러에서 2030년에는 91억 달러에 달할 것으로 예측되며, 2025년부터 2030년까지의 예측 기간 동안 CAGR 5.5%로 성장할 전망입니다. 아시아태평양 시장은 2024년 6.4%로 성장을 지속하여 2030년에는 44억 달러에 달할 것으로 예측되고 있습니다.

본 보고서에서는 세계의 갑상선 질환 진단 및 치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약

제2장 시장 개요

• 개요
• 기존 기술과 신기술
• 갑상선 질환의 진단
• 갑상선 질환의 치료
• Porter's Five Forces 분석
• 거시경제 요인
• 고령화 인구
• 규제 환경
• 암 발생률 증가
• 정부 정책과 협력

제3장 시장 역학

• 시장 성장 촉진요인
• 갑상선암의 이환율 증가
• 갑상선 질환의 유병률 증가
• 갑상선 질환에 대한 의식의 고조와 정책
• 맞춤형 의료의 갑상선 질환의 관리
• 시장 성장 억제요인
• 치료의 부작용
• 저소득 지역에서의 접근 제한
• 시장 기회
• AI 도입
• 고급 치료법
• 시장의 과제
• 의료 격차 및 자금 조달 문제
• 평생 투약 필요성

제4장 규제 상황

• 승인 과정 : 미국
• 승인 과정 : EU
• 승인 프로세스 : 아시아태평양
• 의약품의 승인과 규제
• 레보티록신 기반 치료
• 항갑상선약
• 생물학적 제제 및 바이오시밀러의 규제
• 의료기기 및 진단에 관한 규제
• 현장 진단 및 실험실 검사
• 웨어러블 및 디지털 의료 솔루션
• 장래의 동향과 규제의 변경

제5장 신기술과 개발

• 개요
• 갑상선 질환 진단 분야의 신기술
• 하이브리드 특징 선택 및 딥러닝 프레임워크
• 갑상선 및 부갑상선 수술을 위한 자동 형광 기술
• 재생 의료 및 바이오 엔지니어링
• 바이오웨어러블 기술
• 모바일 앱
• 의약품 및 의료기기의 최근 승인 및 발매
• 특허 분석
• 조사 결과

제6장 시장 세분화 분석

• 세분화 분석
• 핵심 요약
• 시장 분석 : 질병별
• 갑상선 기능 저하증
• 갑상선 기능 항진증
• 갑상선암
• 기타
• 시장 분석 : 유형별
• 요약
• 진단
• 치료
• 시장 분석 : 최종 사용자별
• 요약
• 병원 및 전문 클리닉
• 소매 약국 및 온라인 약국
• 연구 및 학술기관
• 재택 케어
• 지리적 세분화
• 시장 분석 : 지역별
• 요약
• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제7장 경쟁 정보

• 요약
• 주요 기업의 시장 점유율
• 개발 및 전략
• 협정 및 협력 및 파트너십
• 인수

제8장 갑상선 질환의 진단 및 치료 산업에서의 지속 가능성 : ESG의 관점

• ESG: 소개
• 주요 기업의 대처
• ESG 위험 평가
• BCC의 견해

제9장 부록

• 조사 방법
• 출처
• 약어
• 기업 프로파일
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• FRESENIUS SE & CO. KGAA
• GSK PLC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• 신흥 스타트업 기업

영문목차

The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

The North American market for diagnostics and treatment of thyroid gland disorders was valued at $6.6 billion in 2024 and is estimated to increase from $6.9 billion in 2025 to reach $9.1 billion by 2030, at a CAGR of 5.5% from 2025 through 2030.

The Asia-Pacific market for diagnostics and treatment of thyroid gland disorders was valued at $3.0 billion in 2024 and is estimated to increase from $3.2 billion in 2025 to reach $4.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

Report Scope

The report analyzes trends in the global market for diagnostics and treatment of thyroid gland disorders. The report includes global revenue ($ million) for the base year 2024, estimated data for 2025, and for the forecast period of 2026 through 2030. The market is segmented by type of disease, product type, end user and region. The disease types are segmented into hypothyroidism, hyperthyroidism, thyroid cancer, and others. Product types are diagnostics and treatments. The diagnostics market is segmented into diagnostic, blood and imaging tests. The treatment market is segmented into medication, thyroid surgery, thyroid eye disease (TED) treatment and other end users are hospitals, specialty clinics, retail and online pharmacies, research and academic institutions, and patient and home care settings. The regions covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW. North American consists of the U.S., Canada, and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

This report focuses on trends and challenges that affect the market, including emerging technologies. It includes an analysis of the competitive landscape, with the rankings and market shares of the leading companies in the global market. The report has a chapter on environmental, social, and corporate governance (ESG) developments and includes company profiles that covers key financials, product portfolios and recent news.

Report Includes

• 97 data tables and 62 additional tables
• An overview of the current and future global markets for thyroid gland disorder
• An analysis of the global market trends with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by type, disease type, end-user industry, and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Analysis of market opportunities from a Porter's Five Forces perspective, and a value chain analysis considering the prevailing micro- and macro environmental factors
• Coverage of advances in thyroid cancer diagnosis such as genomic tests and treatments, as well as the side effects of current treatments such as radioactive iodine
• Evaluation of ESG practices in the industry, consumer attitudes towards sustainability, risks and opportunity assessment, ratings and matrices
• A patent analysis with emphasis on emerging technologies and new developments in the market
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Amgen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Conventional and Novel Technologies
• Diagnostics in Thyroid Gland Disorders
• Treatment of Thyroid Gland Disorders
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate to High)
• Threat of Substitutes (Low to Moderate)
• Industry Competitiveness (High)
• Macroeconomic Factors
• Aging Population
• Regulatory Environment
• Growing Incidence of Cancer
• Government Policy and Collaboration

Chapter 3 Market Dynamics

• Market Drivers
• Growing Prevalence of Thyroid Cancer
• Growing Prevalence of Thyroid Disorders
• Rising Awareness and Policy Initiatives for Thyroid Disorders
• Managing Thyroid Disorders through Personalized Medicine
• Market Restraints
• Side Effects of Treatment
• Limited Access in Low-Income Regions
• Market Opportunities
• Incorporation of AI
• Advanced Therapeutics
• Market Challenges
• Healthcare Disparities and Funding Challenges
• Requirement for Lifelong Medication

Chapter 4 Regulatory Landscape

• U.S. Approval Process
• EU Approval Process
• Asia-Pacific Approval Process
• Drug Approval and Regulations
• Levothyroxine-Based Treatments
• Anti-Thyroid Medications
• Biologic and Biosimilar Regulations
• Medical Devices and Diagnostics Regulations
• Point-of-Care and Laboratory Tests
• Wearable and Digital Health Solutions
• Future Trends and Regulatory Changes

Chapter 5 Emerging Technologies and Developments

• Overview
• Emerging Technologies in Thyroid Disorder Diagnostics
• Hybrid Feature Selection and Deep Learning Framework
• Autofluorescence Technology for Thyroid and Parathyroid Surgery
• Regenerative Medicine and Bioengineering
• Biowearable Technology
• Mobile Apps
• Recent Approvals and Launches of Drug and Device Products
• Patent Analysis
• Findings

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Key Takeaways
• Market Analysis by Disease Type
• Hypothyroidism
• Hyperthyroidism
• Thyroid Cancer
• Other Diseases
• Market Analysis by Type
• Takeaways
• Diagnostics
• Treatment
• Market Analysis by End User
• Takeaways
• Treatment in Hospitals and Specialty Clinics
• Retail and Online Pharmacies
• Research and Academic Institutes
• Home Care Settings
• Geographic Breakdown
• Market Analysis by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Takeaways
• Market Shares of Leading Companies
• Developments and Strategies
• Agreements, Collaborations and Partnerships
• Acquisitions

Chapter 8 Sustainability in the Diagnostics and Treatment of Thyroid Gland Disorders Industry: ESG Perspective

• Introduction to ESG
• Initiatives by Leading Companies
• ESG Risk Ratings
• BCC Research Viewpoint

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• FRESENIUS SE & CO. KGAA
• GSK PLC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• Emerging Start-ups/ Market Disruptors